A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin…

Overview of attention for article published in Blood, November 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 3 news outlets

blogs: 1 blog

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 5 news stories from 3 outlets.

Engineered Immune Cell Therapy Reduces Toxicity in Clinical 1 Trial | Immunology

LabRoots, 14 Dec 2023

A novel immune cell therapy known as Chimeric Antigen Receptor (CAR) T cell therapy has recently demonstrated efficacy in B-cell…

Engineered Immune Cell Therapy Reduces Toxicity in Clinical 1 Trial | Immunology

LabRoots, 14 Dec 2023

A novel immune cell therapy known as Chimeric Antigen Receptor (CAR) T cell therapy has recently demonstrated efficacy in B-cell…

Engineered Immune Cell Therapy Reduces Toxicity in Clinical 1 Trial | Immunology

LabRoots, 14 Dec 2023

A novel immune cell therapy known as Chimeric Antigen Receptor (CAR) T cell therapy has recently demonstrated efficacy in B-cell…

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Medical News, 12 Dec 2023

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.